Here, as a first attempt, since we are dealing with a neurological disease, we chose to test GS967, because this compound had been shown to reduce anomalous persistent currents in two mouse models affected by a severe encephalopathy (Nav1.6) and by Dravet syndrome (Nav1.1), respectively. This evidence concerns the gene SCN1A and encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy.